Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Chief Commercial Officer | January 31, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atea Pharmaceuticals, Inc.
Report date January 31, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,594 |
Ending reported balance
After 2026-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-31 · Exercise / conversion · Acquired 42,083 · Balance 94,164 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-01-31 · Tax withholding · Disposed 11,570 · Balance 82,594 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-31 · Exercise / conversion · Disposed 33,333 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-31 · Exercise / conversion · Disposed 8,750 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2036-01-30 | Direct | 119,520 |
Reported balance
After 2026-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-31 · Grant · Acquired 119,520 · Balance 119,520 F4: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030. |
| Common StockSEC Table I · non-derivative | IndirectHeld by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust | 82,508 |
Reported balance
Holding disclosure · report date 2026-01-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 82,508 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F4: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2026 Filed Feb 4, 2026 00:47 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 119,520 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001193125-26-036272 · ownership.xml · derivative · entry 6 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,520 Underlying: Common Stock · 119,520 shares Expires 2036-01-30 F4 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 00:47 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036272 · ownership.xml · derivative · entry 5 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. F3 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 00:47 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036272 · ownership.xml · derivative · entry 4 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. F2 · derivative.expiration_date: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 00:47 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 11,570 | $4.24 | $49,056.80 |
DisclosureSEC source: 0001193125-26-036272 · ownership.xml · nonDerivative · entry 2 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,594 Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 00:47 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 42,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036272 · ownership.xml · nonDerivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 23:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 132,800 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0000950170-25-013852 · ownership.xml · derivative · entry 7 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,800 Underlying: Common Stock · 132,800 shares Expires 2035-01-30 F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 23:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013852 · ownership.xml · derivative · entry 6 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 23:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013852 · ownership.xml · derivative · entry 5 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F3 · derivative.expiration_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 23:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 11,517 | $3.06 | $35,242.02 |
DisclosureSEC source: 0000950170-25-013852 · ownership.xml · nonDerivative · entry 3 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,081 Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 23:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013852 · ownership.xml · nonDerivative · entry 2 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,598 F2 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs"). Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 23:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013852 · ownership.xml · nonDerivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 01, 2024 Filed Feb 3, 2024 02:25 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 11,819 | $3.84 | $45,420.42 |
DisclosureSEC source: 0000950170-24-010968 · ownership.xml · nonDerivative · entry 2 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,515 F2 · shares: Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 25, 2022. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 02:25 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 132,800 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-24-010968 · ownership.xml · derivative · entry 5 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,800 Underlying: Common Stock · 132,800 shares Expires 2034-01-30 F4 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 02:25 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010968 · ownership.xml · derivative · entry 4 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 33,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F3 · derivative.expiration_date: The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 02:25 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-010968 · ownership.xml · nonDerivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 23:26 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000899243-23-003600 · doc4.xml · derivative · entry 2 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-01-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 23:26 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003600 · doc4.xml · derivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. F2 · derivative.expiration_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 22:15 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0000899243-22-004186 · doc4.xml · derivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 21:51 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 117,300 | $0.00 Strike: $73.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003868 · doc4.xml · derivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,300 Underlying: Common Stock · 117,300 shares Expires 2031-01-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:04 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionSeries B Convertible Preferred Stock · Derivative | 82,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030323 · doc4.xml · derivative · entry 2 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust Disclosed balance after: 0 Underlying: Common Stock · 82,508 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:04 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionCommon Stock | 82,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030323 · doc4.xml · nonDerivative · entry 1 Vavricka John · CIK 0001829630 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust Disclosed balance after: 82,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.